<DOC>
	<DOCNO>NCT01746979</DOCNO>
	<brief_summary>This Phase 3 trial randomize , double-blind , placebo-controlled trial gemcitabine combination TH-302 compare gemcitabine combination placebo subject locally advanced unresectable metastatic pancreatic adenocarcinoma . Randomized subject receive TH-302 plus gemcitabine gemcitabine plus placebo 4-week cycle evidence progressive disease , intolerable toxicity , subject discontinues trial reason ( example , withdrawal consent ) . The primary efficacy endpoint overall survival ( OS ) time . The data cut-off statistical analysis primary secondary endpoint reach 508 event ( death ) report . No planned interim analysis conduct . An Independent Safety Monitoring Board ( ISMB ) provide periodic evaluation unblinded safety data ensure subject safety validity scientific merit study . A total 660 subject enrol .</brief_summary>
	<brief_title>Clinical Trial Testing TH-302 Combination With Gemcitabine Previously Untreated Subjects With Metastatic Locally Advanced Unresectable Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>At least 18 year age Locally advance unresectable metastatic pancreatic ductal adenocarcinoma proven histology cytology previously untreated chemotherapy systemic therapy : Radiosensitizing dose 5fluorouracil ; Radiosensitizing dos gemcitabine relapse occur least 6 month completion gemcitabine ; Neoadjuvant chemotherapy relapse occur least 6 month surgical resection ; Adjuvant chemotherapy relapse occur least 6 month completion adjuvant chemotherapy Measurable disease ( least one target lesion outside previous radiation field ) nonmeasurable disease RECIST v.1.1 criterion Documentation disease progression since prior therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy least 3 month Acceptable liver , renal function acceptable hematological status Other protocol define inclusion criterion may apply New York Heart Association ( NYHA ) Class III IV congestive heart failure , myocardial infarction within 6 month prior date randomization , unstable arrhythmia symptomatic peripheral arterial vascular disease Symptomatic ischemic heart disease Known brain , leptomeningeal epidural metastasis ( unless treat well control least 3 month ) Previous malignancy pancreatic cancer last 5 year , except adequately treat nonmelanoma skin cancer preinvasive cancer cervix Severe chronic obstructive pulmonary disease hypoxemia Major surgery , diagnostic surgery , less equal 28 day prior date randomization . Subject must completely recover surgery Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Treatment pancreatic cancer radiation therapy surgery less equal 28 day prior date randomization Prior therapy hypoxic cytotoxin Subjects participate investigational drug device trial less equal 28 day prior Day 1 first cycle Known infection Human Immunodeficiency Virus ( HIV ) , active infection Hepatitis B Hepatitis C Subjects exhibit allergic reaction structural compound similar TH302 drug product excipients gemcitabine excipients Other protocol define exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>TH-302</keyword>
	<keyword>Evofosfamide</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>EMR200592-001</keyword>
</DOC>